Dai ichi Life Insurance Company Ltd Buys 2,697 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Dai ichi Life Insurance Company Ltd increased its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 5.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 52,146 shares of the company’s stock after buying an additional 2,697 shares during the period. Dai ichi Life Insurance Company Ltd’s holdings in Teva Pharmaceutical Industries were worth $847,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Maple Rock Capital Partners Inc. boosted its stake in Teva Pharmaceutical Industries by 68.3% in the first quarter. Maple Rock Capital Partners Inc. now owns 4,363,401 shares of the company’s stock valued at $61,568,000 after acquiring an additional 1,770,000 shares in the last quarter. Glenview Capital Management LLC acquired a new stake in Teva Pharmaceutical Industries during the 4th quarter valued at approximately $16,752,000. Iron Triangle Partners LP boosted its holdings in shares of Teva Pharmaceutical Industries by 113.1% in the 1st quarter. Iron Triangle Partners LP now owns 2,769,864 shares of the company’s stock valued at $39,083,000 after acquiring an additional 1,469,864 shares during the last quarter. Norges Bank acquired a new position in Teva Pharmaceutical Industries during the fourth quarter valued at $14,376,000. Finally, Hsbc Holdings PLC lifted its holdings in shares of Teva Pharmaceutical Industries by 242.6% in the 4th quarter. Hsbc Holdings PLC now owns 1,597,178 shares of the company’s stock valued at $16,667,000 after buying an additional 1,130,969 shares during the period. 54.05% of the stock is currently owned by institutional investors.

Insider Activity

In other Teva Pharmaceutical Industries news, insider Eric A. Hughes sold 24,537 shares of the business’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $17.25, for a total value of $423,263.25. Following the completion of the transaction, the insider now owns 45,060 shares in the company, valued at $777,285. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Price Performance

TEVA stock opened at $18.07 on Tuesday. Teva Pharmaceutical Industries Limited has a 52-week low of $8.06 and a 52-week high of $19.08. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 2.52. The stock has a market cap of $20.47 billion, a price-to-earnings ratio of -44.07, a price-to-earnings-growth ratio of 1.26 and a beta of 0.88. The business has a fifty day moving average of $17.59 and a two-hundred day moving average of $15.99.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Wednesday, July 31st. The company reported $0.58 earnings per share for the quarter, topping the consensus estimate of $0.55 by $0.03. The company had revenue of $4.16 billion during the quarter, compared to analyst estimates of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 2.73% and a positive return on equity of 39.66%. As a group, research analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.33 earnings per share for the current year.

Wall Street Analysts Forecast Growth

TEVA has been the subject of several recent research reports. Bank of America lifted their target price on shares of Teva Pharmaceutical Industries from $18.00 to $21.00 and gave the company a “buy” rating in a report on Thursday, May 30th. Jefferies Financial Group lifted their price target on Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the company a “buy” rating in a research note on Thursday, June 27th. Barclays raised their price objective on Teva Pharmaceutical Industries from $21.00 to $22.00 and gave the company an “overweight” rating in a report on Thursday, August 1st. Argus raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 target price for the company in a research note on Wednesday, July 10th. Finally, StockNews.com raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 3rd. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $18.89.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.